Transaction | Jotup

SEQUANA MEDICAL LAUNCHES EQUITY PLACEMENT AND PROVIDES TRADING UPDATE

Retrieved on:

Wednesday, March 20, 2024

(ii) Finalizing the North American pivotal study in recurrent and refractory liver ascites (POSEIDON) towards secondary endpoint readout planned for Q2 2024.

Key Points:

(ii) Finalizing the North American pivotal study in recurrent and refractory liver ascites (POSEIDON) towards secondary endpoint readout planned for Q2 2024.
The Offering shall be structured as a private placement of new shares via an accelerated bookbuilding, which will commence immediately.
Trading in Sequana Medical shares on the regulated market of Euronext Brussels will be suspended during the bookbuilding period.
Trading in the shares is expected to resume following the publication of the results of the Offering.

Steppe Gold Ltd. Announce Extension of Binding Term Sheet

Retrieved on:

Tuesday, March 19, 2024

Extension, Binding, TSX, Transaction, News, Gold

ULAANBAATAR, Mongolia, March 19, 2024 (GLOBE NEWSWIRE) -- Steppe Gold Ltd. (TSX: STGO) (OTCQX: STPGF) (FSE: 2J9) (“Steppe Gold”) is pleased to announce the extension (the “Extension Letter Agreement”) of the binding term sheet entered with, among other parties, Boroo Gold LLC (“Boroo Gold”) dated January 18, 2024 (the “Binding Agreement”), pursuant to which Steppe Gold, either directly or through a wholly-owned subsidiary, will acquire all of the issued and outstanding common shares of Boroo Gold in an all-share transaction (the “Proposed Transaction”).

Key Points:

ULAANBAATAR, Mongolia, March 19, 2024 (GLOBE NEWSWIRE) -- Steppe Gold Ltd. (TSX: STGO) (OTCQX: STPGF) (FSE: 2J9) (“Steppe Gold”) is pleased to announce the extension (the “Extension Letter Agreement”) of the binding term sheet entered with, among other parties, Boroo Gold LLC (“Boroo Gold”) dated January 18, 2024 (the “Binding Agreement”), pursuant to which Steppe Gold, either directly or through a wholly-owned subsidiary, will acquire all of the issued and outstanding common shares of Boroo Gold in an all-share transaction (the “Proposed Transaction”).
The Extension Letter Agreement extends the exclusivity period between Steppe Gold and Boroo Gold in the Binding Agreement from March 29, 2024 to April 12, 2024, or such earlier or later time as Steppe Gold and Boroo Gold mutually agree, in order to provide more time for the parties to complete due diligence and enter into a definitive agreement.
For more information on the Transaction, please see the news release dated January 22, 2024 which is available on SEDAR+ at www.sedarplus.ca.

Titan Announces Merger Agreement with Conavi

Retrieved on:

Monday, March 18, 2024

TSX Venture Exchange, Agreement, Health Canada, IP, OCT, RAS, Chairperson, Toronto Stock Exchange, Consolidation, Combined, Reverse, Concurrency, Food, TMD, TSX, Transaction, IVUS, Security (finance)

TORONTO, Ontario, March 18, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) is pleased to announce that it has entered into a definitive amalgamation agreement (the “Amalgamation Agreement”) dated March 17, 2024 with Conavi Medical Inc. (“Conavi”) to combine the companies in an all-stock transaction.

Key Points:

TORONTO, Ontario, March 18, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) is pleased to announce that it has entered into a definitive amalgamation agreement (the “Amalgamation Agreement”) dated March 17, 2024 with Conavi Medical Inc. (“Conavi”) to combine the companies in an all-stock transaction.
Under the terms of the Agreement, Titan will acquire all of the issued and outstanding shares of Conavi (the “Conavi Shares”) and in exchange Conavi shareholders will be issued common shares of Titan (the “Combined Entity Shares”).
Throughout 2023, it was made clear to Titan that a merger with another RAS company was not a viable option and Titan broadened its search for a merger partner beyond RAS.
The Titan Board is unanimous in its decision to execute the Amalgamation Agreement and to recommend this Transaction to its shareholders (the “Titan Shareholders”).

KEON CAPITAL INC. EXECUTES DEFINITIVE AGREEMENTS RESPECTING PROPOSED TRANSACTION WITH FRAME HOLDINGS INC.

Retrieved on:

Wednesday, March 13, 2024

Combination, TSX Venture Exchange, Private, Minority, News, Business analyst, Multilateral, Transaction, Policy, Security (finance)

Vancouver, B.C., March 13, 2024 (GLOBE NEWSWIRE) -- Keon Capital Inc. (“Keon” or the “Company”) (TSXV: KEON.H) is pleased to provide an update respecting its previously announced transaction (the “Transaction”) with Frame Holdings Inc. (“Frame”) pursuant to which Keon will acquire all of the issued and outstanding Frame shares from the Frame shareholders (see Keon’s news release dated November 6, 2023 announcing the execution of an LOI respecting the Transaction).

Key Points:

Vancouver, B.C., March 13, 2024 (GLOBE NEWSWIRE) -- Keon Capital Inc. (“Keon” or the “Company”) (TSXV: KEON.H) is pleased to provide an update respecting its previously announced transaction (the “Transaction”) with Frame Holdings Inc. (“Frame”) pursuant to which Keon will acquire all of the issued and outstanding Frame shares from the Frame shareholders (see Keon’s news release dated November 6, 2023 announcing the execution of an LOI respecting the Transaction).
The Transaction is structured as a three-cornered amalgamation (the “Amalgamation”), with Frame amalgamating with Subco and becoming a wholly-owned subsidiary of Keon.
Shareholders of Frame will receive one common share in the capital of Keon in exchange for each outstanding common share of Frame held by them, with Keon expected to issue an aggregate of approximately 40,000,000 Keon shares (assuming the minimum Frame financing of $2,000,000) to the Frame shareholders under the Transaction.
In connection with the Transaction, Keon will conduct a 2.8:1 share consolidation of issued and outstanding Keon common shares (the “Keon Share Consolidation”), and any shares issued to Frame shareholders under the Transaction will be on a post-consolidation basis.

Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings

Retrieved on:

Tuesday, March 12, 2024

Nature, EDGAR, TSX, Transaction

"We thank our shareholders for their backing of this transaction," said Carolyn Egbert, Chair of Aeterna.

Key Points:

"We thank our shareholders for their backing of this transaction," said Carolyn Egbert, Chair of Aeterna.
“This is an excellent outcome that supports the creation of what we believe will be a long-term sustainable business, optimally positioned to deliver value to the biopharma sector, and to Aeterna and Ceapro shareholders."
"We are thrilled by the support for this transaction displayed by our valued securityholders at today’s meeting,” echoed Ronnie Miller, Chairman of Ceapro.
The combined company is expected to be listed on the Nasdaq and the TSX, subject to the receipt of all necessary approvals.

Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings

Retrieved on:

Tuesday, March 12, 2024

Nature, EDGAR, TSX, Transaction

"We thank our shareholders for their backing of this transaction," said Carolyn Egbert, Chair of Aeterna.

Key Points:

"We thank our shareholders for their backing of this transaction," said Carolyn Egbert, Chair of Aeterna.
“This is an excellent outcome that supports the creation of what we believe will be a long-term sustainable business, optimally positioned to deliver value to the biopharma sector, and to Aeterna and Ceapro shareholders."
"We are thrilled by the support for this transaction displayed by our valued securityholders at today’s meeting,” echoed Ronnie Miller, Chairman of Ceapro.
The combined company is expected to be listed on the Nasdaq and the TSX, subject to the receipt of all necessary approvals.

Whole Earth Brands Reports Fourth Quarter and Full Year 2023 Results

Retrieved on:

Tuesday, March 12, 2024

Consolidated, Growth, Sale, CPG, Lemon Popsicle, Transaction, Corporation, Video game

Adjusted gross profit was $44.9 million, compared to $40.1 million in the prior year fourth quarter.

Key Points:

Adjusted gross profit was $44.9 million, compared to $40.1 million in the prior year fourth quarter.
Reported gross profit margin increased to 26.7% in the fourth quarter of 2023, compared to 20.4% in the prior year period.
Adjusted gross profit margin increased to 29.7%, compared to 28.9% in the prior year fourth quarter.
Corporate expenses for the fourth quarter of 2023 were $6.4 million, compared to $6.9 million of expenses in the prior year period.

Tricon Residential Inc. Receives Final Court Approval for Take Private by Blackstone Real Estate

Retrieved on:

Friday, April 5, 2024

Residential Building & Real Estate, Commercial Building & Real Estate, Construction & Property, REIT, Indian stock exchange, Letter, TCN, Registered, Toronto Stock Exchange, TSX, Arrangement, Investment Canada Act, Transaction

Tricon Residential Inc. (NYSE: TCN, TSX: TCN) (“Tricon” or the “Company”) today announced that the Ontario Superior Court of Justice (Commercial List) has granted a final order approving its previously announced statutory plan of arrangement under the Business Corporations Act (Ontario) (the “Arrangement”) pursuant to which Blackstone Real Estate Partners X, together with Blackstone Real Estate Income Trust, Inc. will acquire all of the outstanding common shares of the Tricon (“Common Shares”) for US$11.25 per Common Share in cash (the “Transaction”).

Key Points:

Tricon Residential Inc. (NYSE: TCN, TSX: TCN) (“Tricon” or the “Company”) today announced that the Ontario Superior Court of Justice (Commercial List) has granted a final order approving its previously announced statutory plan of arrangement under the Business Corporations Act (Ontario) (the “Arrangement”) pursuant to which Blackstone Real Estate Partners X, together with Blackstone Real Estate Income Trust, Inc. will acquire all of the outstanding common shares of the Tricon (“Common Shares”) for US$11.25 per Common Share in cash (the “Transaction”).
Completion of the Transaction remains subject to the satisfaction or waiver of certain customary closing conditions, including the receipt of regulatory approval under the Investment Canada Act.
Subject to the satisfaction or waiver of all of the conditions to the Transaction, the Transaction is expected to be completed in the second quarter of this year.
Exchange Act”).

NICE Actimize Honored for Best Transaction Monitoring Solution by Regulation Asia’s 2023 Excellence Awards

Retrieved on:

Thursday, April 4, 2024

Finance, Security, Professional Services, Technology, Fintech, NICE Ltd., Machine learning, Transaction, Regulation, SAM, AML

NICE Actimize, a NICE (Nasdaq: NICE) business, was recently recognized by the “ Regulation Asia Awards for Excellence 2023 ” with its award for the “Best Solution - Transaction Monitoring” in its “Best Solutions – Financial Crime” category.

Key Points:

NICE Actimize, a NICE (Nasdaq: NICE) business, was recently recognized by the “ Regulation Asia Awards for Excellence 2023 ” with its award for the “Best Solution - Transaction Monitoring” in its “Best Solutions – Financial Crime” category.
According to Regulation Asia’s judging panel, NICE Actimize was recognized for its comprehensive suite of AML solutions, which features its flagship transaction monitoring solution, Suspicious Activity Monitoring (SAM) , along with a robust portfolio of additional capabilities for screening, reporting, customer due diligence, and other components.
The transaction monitoring solution offers more than 70 AML scenarios and over 250 engineered models to choose from for deployment in a financial institution’s AML program.
The judging panel also credited NICE Actimize for the sophistication of its transaction monitoring capabilities, including its ability to leverage advanced technologies including data analytics and AI/machine learning.

Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)

Retrieved on:

Tuesday, April 2, 2024

The U.S. FDA's approval of LIKMEZ highlighted Appili’s capacity to identify and develop significant opportunities within the infectious disease domain.

Key Points:

The U.S. FDA's approval of LIKMEZ highlighted Appili’s capacity to identify and develop significant opportunities within the infectious disease domain.
Appili licensed the manufacturing and commercialization rights in the U.S. and other selected territories to Saptalis Pharmaceuticals, LLC (“Saptalis”).
Appili, in collaboration with Saptalis, continued the product's development, ultimately achieving FDA approval in the United States.
With FDA approval, future revenue is expected to be derived from milestone payments and royalties from Saptalis under the license agreement.